Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
2(29%)
Results Posted
150%(3 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
1
14%
Ph phase_3
2
29%
Ph phase_4
1
14%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Active, not recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 32 (28.6%)
Phase 41 (14.3%)

Trials by Status

active_not_recruiting229%
terminated343%
completed229%

Recent Activity

2 active trials
Showing 5 of 7
terminatedphase_1

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

NCT05198843
active_not_recruitingphase_2

IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

NCT06466278
active_not_recruitingphase_3

EPA for Metastasis Trial 2

NCT03428477
terminatedphase_4

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
terminatedphase_3

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

NCT02422446
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05198843Phase 1

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Terminated
NCT06466278Phase 2

IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion

Active Not Recruiting
NCT03428477Phase 3

EPA for Metastasis Trial 2

Active Not Recruiting
NCT04505098Phase 4

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Terminated
NCT02422446Phase 3

Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects

Terminated
NCT04177680Phase 2

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Completed
NCT04412018Phase 2

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7